Pfizer on Thursday entered into an exclusive license agreement with Massachusetts-based biotech Nona Biosciences to develop the mesothelin-targeting antibody-drug conjugate HBM9033 in solid tumors.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,